Friday, February 18th, 2011 - TomoTherapy Incorporated
Leading Hong Kong Hospital Is Recipient and First to Order Two TomoHD(R) Treatment Systems Worldwide

MADISON, WI--(Marketwire) - TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that it has shipped its 350th treatment system. The milestone unit is the first of two TomoHD(tm) treatment systems that will be installed at the prestigious Hong Kong Sanatorium and Hospital (HKSH), which in 2005 became the first treatment center in Asia to embrace TomoTherapy technology.

With the addition of the TomoHD treatment systems, HKSH will expand its TomoTherapy treatment program to meet high patient demand and bring advanced image-guided, intensity-modulated radiation therapy (IG-IMRT) capabilities and treatment quality to a broader patient population.

"From our experience using TomoTherapy technology we have become accustomed to the integrated workflow and exceptional treatment quality that the platform affords our clinical staff and cancer patients. The TomoHD system installations will allow us to maximize use of this important technology within our busy clinic," said Wyman Li, Manager (Administration) of HKSH.

By combining TomoHelical(tm) and TomoDirect(tm) delivery modes, the TomoHD treatment system is designed to help radiation oncology teams efficiently target a broad range of cases requiring radiation therapy. Using either delivery modality, clinicians can efficiently acquire a low-dose helical CT image immediately prior to each daily treatment, to help ensure precise patient positioning based on internal anatomy. Then, with the same equipment used for imaging, the treatment team can deliver highly-precise radiation to complex target volumes in a continuous, 360-degree pattern using the TomoHelical delivery mode. The TomoDirect delivery mode facilitates a non-rotational delivery option that enables clinicians to quickly plan and deliver advanced TomoTherapy radiation treatments with a series of linear beam paths, rather than a single helical delivery path, thereby improving efficiency in the treatment of more common target volumes.

"HKSH has established strict standards for all procedures in order to maintain high quality in delivering individualized treatment for each patient," said B.Y. Lee, Deputy Manager (Administration) of HKSH. "The availability of TomoTherapy technology has certainly helped support these efforts, but we saw a need to expand access to its benefits. The TomoHD system, with its TomoDirect delivery option, brings added versatility to a proven platform. We are confident these systems can provide state-of-the-art solutions for our high-demand environment for many years to come."

Patient treatments on the TomoHD treatment system are expected to commence in March. HKSH plans to install the second TomoHD treatment system later in 2011.

"TomoTherapy is very pleased to announce the shipment of our 350th treatment system, a key milestone in both the adoption and evolution of our radiation therapy platform," said Fred Robertson, TomoTherapy's president and CEO. "We are equally pleased to announce the first dual order of TomoHD treatment systems worldwide. Hong Kong Sanatorium is another longstanding partner that has chosen to embrace the increased flexibility and throughput capabilities that the TomoHD system offers. We look forward to bringing this technology to Hong Kong."

About Hong Kong Sanatorium and Hospital

Hong Kong Sanatorium & Hospital (HKSH) is one of the leading private hospitals in Hong Kong. HKSH is committed to ensuring quality in service and excellence in care. It also strives to advance in medical education and research, with an overriding concern for the public good. For more details, please visit www.hksh.com/eng.

Contact Profile

TomoTherapy Incorporated


TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi-Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD(tm) treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile(tm) relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2011 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, Hi-Art, TomoHD and the TomoTherapy logo are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Investor Contact:

Thomas E. Powell

Chief Financial Officer

608.824.2800

[email protected]



Media Contacts:

Kevin O'Malley

Director, Corporate Communications

608.824.3384

[email protected]



Susan Lehman

Rockpoint Public Relations

510.832.6006

[email protected]
Kevin O'Malley Director, Corporate Communications
P: 608.824.3384
W: www.hksh.com/eng

Keywords

Leading Hong Kong Hospital Is Recipient and First to Order Two TomoHD(R) Treatment Systems Worldwide

Categories

Sharing

More Formats